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radiotherapy may be unnecessary for pT3N0
rectal cancer
Jun-xin Wu*, Yu Wang, Na Chen, Lu-chuan Chen, Peng-gang Bai and Jian-ji Pan*Abstract
Background: Due to the Total Mesorectal Excision (TME) surgery made a good local control,the role of radiotherapy
in the treatment of pT3N0 rectal cancer is debated and whether this group of patiens were overtreated has been a
controversy recently. This study aimed to evaluate the value of adjuvant radiation after TME and survival outcome
for patients with pT3N0 rectal adenocarcinoma.
Methods: From January 2003 to December 2011, a total of 141 patients with pT3N0 rectal cancer after radical resection
with the principle of Total Mesorectal Excision (TME) were enrolled. Among them, 42 patients (29.8%) got adjuvant
chemotherapy (CT) and the remaining cohort received chemoradiotherapy (CRT). The 5-year overall survival rate (OS),
5-year disease free survival rate (DFS), 5-year local recurrence free survival rate (LRFS), 5-year local recurrence rate (LRR)
and the prognostic factor of this cohort were analyzed.
Results: The median follow-up interval time was 44 months. The 5-year OS and DFS rates were 82.4% and 71.9%
for the whole group. There were no significant differences in 5-year OS (83.3% vs 72.4%, P = 0.931) or LRFS rates
(81.7% vs 74.5%, P = 0.157) for patients between CT group and CRT group. Multivariate cox regression analysis
suggests that preoperative serum CEA level, number of lymph nodes inspected, perirectal fat infiltration were
independent prognostic factors for 5-year DFS. The recurrence rate was not affected by radiotherapy for patients
with lower and midrectal cancer.
Conclusions: For the patients with pT3N0 rectal cancer, addition radiation after TME surgery made no significant
differences in survival rate and local recurrence rate. The effect of adjuvant radiotherapy needs further evaluation.
Keywords: Rectal cancer, Post-operative radiotherapy, Prognosis factorsIntroduction
Rectal cancer is still a common tumor among the world,
while the major treatment for patients with a rectal ma-
lignancy is radical surgical excision. For patients with
resectable rectal cancer, an optimal surgery could get a
satisfactory local control; while for those with advanced
tumors, a curative resection may be especially difficult
because of the special location of pelvis and always with
high local failure rates [1]. As a result, a multidisciplinary
synthetic therapy is of great important value. In the 1990s,
several researches have suggested that postoperative* Correspondence: junxinwu@126.com; panjianji@126.com
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reproduction in any medium, provided the orchemoradiotherapy can cut down local recurrence rates
[2,3]. So the US National Institutes for Health advocated
that the postoperative chemoradiotherapy as standard
regimen for patients with stage II or III rectal cancer [4].
Of note, all these previous researches were conducted in
the times of conventional surgery method. More over,
among the patients involved in previous studies, the
respective proportion of patients with stage II and III
remained unknown and the separate survival outcome of
stage II rectal cancer were not illuminated too. Nowadays,
radical radical surgery with the principle of TME (low an-
terior resection LAR or abdominalperineal resection APR)
could lower the local recurrence rate significantly [5,6].
The TME has showed superior results than conventional
surgery and has been the standard operation form for a. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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the new times, the effect of conventional trimodality ther-
apy (surgery plus chemotherapy plus radiotherapy) for
stage II and III rectal cancer seems to be reconsidered.
Consequently, the real benefit of addition radiotherapy
after surgery was a question need to be investigated [7].
As mentioned above, for the pT3N0 rectal patients, sev-
eral retrospective studies showed the low rates of local re-
currence ranging from 4.1% to 6.5% after TME surgery
alone [5,6]. What’s more, many studies have showed the
addition of radiation therapy did not improve the survival
outcome and local recurrence rate [7-9]. This result in
favor of the point of view that for pT3N0 rectal cancer,
routine adjuvant radiation therapy after TME may be un-
necessary and overtreatment. Many researchers argue that
the pT3N0 rectal cancer may have an “intermediate” risk
of recurrence, and suggest that the radiation therapy need
further investigated [10,11]. To evaluate the effect of adju-
vant radiotherapy in patients with T3N0 rectal cancer after
TME, we studied the influence of adjuvant radiotherapy




Patients with resectable adenocarcinoma and treated with
TME at Fujian Provincial Cancer Hospital between January
2003 and December 2011 were collected. The patient selec-
tion criteria come as follows: (1) between 20–80 years old;
(2) without neo-adjuvant chemotherapy and radiotherapy;
(3) received radical resection with the principle of TME; (4)
biopsy-proven pT3N0 rectal cancer according to the 7th
version of AJCC guideline; (5) no evidence of distant metas-
tases and serious comorbidity before surgery; (6) received
adjuvant chemotherapy (CT) after surgery. Ultimately, 141
patients were included in this study. Patients were split
into CRT and CT group and evaluated for age, sex, pre-
operative serum carcinoembryonic antigen (CEA) level,
histologic differentiation, cell histology, grade of differenti-
ation, total number of lymph nodes retrieved, lymphovas-
cular invasion, adjuvant radiotherapy, development of
recurrence or metastasis and survival. Before surgery, pa-
tients received a complete physical examination, blood
routine test, liver and renal function test, proctoscopy, pel-
vic CT or MRI, chest X-ray and the level of CEA. Those
who had a poor physical condition or metastasis were ex-
cluded from our study.
Treatment
Surgery method: except the upper rectal cancer (10 cm
above the anal verge), all patients got surgery with the
principle of TME. The operation method was selected ac-
cording to the digital rectal and proctoscopy examination.
LAR was performed in 97 patients; the remaining 44patients underwent APR. The surgery were operated by at
least two of experienced surgeons. The hypogastric nerve,
pelvic autonomic nerve plexus and arteria rectalis media
were protected as far as possible, lymph drainage area and
fat tissue were removed. The distal mesorectal margin was
at least 2 cm away from the tumor, for those with a distance
ranging from 1 to 2 cm from the anal verge; an intra-
operative frozen pathological examination should be
conducted to confirm the negative surgical margins.
Chemotherapy program: All of the patients received ad-
juvant chemotherapy or concurrent chemoradiotherapy.
The 5-Fluorouracil (5-FU) -based chemotherapy program
consisted of 2250 mg/m2 of 5-FU civ for 46 hours and
400 mg/m2 of CF for d1, and Oxaliplatin for d1 every
14 days for 8–12 cycles. In case of patients treated by
oralling Xeloda, the patients took orally 1250 mg/m2 twice
daily days 1-14 every 3 weeks to a total of 6 months.
Concurrent chemotherapy: 225 mg/m2 of 5-Fu over
24 hours 5 days/week during radiotherapy or took
Xeloda 825 mg/m2 twice daily 5 days per week during
radiotherapy.
Radiation therapy: for the CRT group, the patients began
additional radiation therapy within 4 weeks after TME. Of
these patients, 27 got conventional radiotherapy,11 re-
ceived three dimensional conformal radiation therapy, the
remaining 4 received Intensity Modulated Radiation Ther-
apy. A 6 MV dual photon linear accelerator was used to
deliver the X-ray and three or five-field box technique was
applied to the treatment planning. The radiation field was
as follows: the upper bound was the level of L5-S1, the
lower bound was the obturator formamen (Dixon) or
1.5 cm inferior of the metal sign (Mile’s), the lateral bound
was 2.0 cm lateral to the widest bony margin of the true
pelvis. A total dose of 50 Gy was delivered in 25 fractions
of 2 Gy per day.
Definition of treatment failure
Through reading the follow up data of the 141 patients,
the treatment failures were found out. Local-failure was
defined as any recurrence occured within the pelvis,
including the tumor bed, regional lymph nodes, anasto-
mosis, or perineal scar. While recurrence detected in the
liver, lung, brain, and other organs or lymph nodes outside
the pelvis were regarded as distant failure.
Follow up
Patients were followed up routinely at 3-month intervals
for the first 2 years, at 6-month intervals for the next
5 year, and once a year thereafter. The follow up examin-
ation consisted of a physical examination, measuring of
CEA, chest X-rays, the whole body ECT, abdominal and
pelvic CT or MRI. Survival time was calculated from the
date of surgery to the date of die or loss to follow-up;
local-recurrence free survival LRFS was from the date of
Table 1 Clinicopathologic characteristics of patients
Characteristics CT
n = 99 (%)
CRT
n = 42 (%)
P value
Age, years 56 56.5 0.814
<50 31 (31) 14 (33)
≥50 68 (69) 28 (67)
Sex 0.966
Male 68 (69) 29 (69)
Female 31 (31) 31 (31)
Median Karnofsky scores 90 90
Preoperative CEA (n g/m L) 0.088
<5 66 (67) 34 (81)
≥5 33 (33) 8 (19)
Distance to anal (cm) 0.003
0-5 34 (34) 27 (64)
6-10 44 (44) 12 (29)
11-15 21 (21) 3 (7)
Surgical type 0.000
<Dixon 79 (80) 18 (43)
Miles 20 (20) 24 (57)
Histologic type 1.000
Adenocarcinoma 94 (95) 40 (95)
Mucinous adenocarcinoma 5 (5) 2 (5)
Grade of differentiated 0.665
Well 15 (15) 9 (21)
Moderately 81 (82) 32 (76)
Poor 3 (3) 1 (3)
Maximum diameter (cm) 0.900
<5 53 (54) 22 (52)
≥5 46 (46) 20 (48)
Number of retrieved lymph nodes 37 (37) 0.001
<15 62 (63) 29 (69)
≥15 13 (31)
Lymph-vascular invasion 0.084
Yes 3 (3) 6 (14)
No 96 (97) 36 (86)
Perirectal fat infiltration 0.323
Yes 36 (36) 18 (43)
No 63 (64) 24 (57)
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survival DFS was time from the date of surgery to the date
of local recur, metastasis or die of the rectal cancer.
Statistical analysis
SPSS 17.0 was used to analysis the data. 5-year OS, DFS
and LRFS curves were calculated according to the
Kaplan-Meier method and log rank test was used to dis-
tinguish the differences between groups. Chi-square tests
was used to paired the clinicopathologic characteristics
of two groups. The Cox regression was used for examin-
ing the independent factors associated with survival out-
come. P < 0.05 was considered statistically significant.
Results
Clinicopathologic characteristics
Of the 141 patients, 42 received CRT, 99 accepted CT. All
of the patients had a Karnofsky score higher than 90 point.
Radiotherapy was performed significantly more commonly
in those with lower rectal cancer (P = .003) and those with
less number of lymph nodes (P = .001). The mean number
of the lymph nodes was 16.15 (range, 0-50). In addition to
above,the two groups were well matched in other clinico-
pathologic items such as age, sex, pre-operative level of
CEA, histological type, grade of differentiation, maximum
diameter of tumor, lymph-vascular invasion, perirectal fat
infiltration (Table 1).
Follow up and recurrence
The median follow up time was 44 months (range, 3-104
months). The proportion of patients followed up more
than 60 and 36 months were 63.8% and 22%. During the
follow up, a total of 23 patients (16.3%) relapsed. The
5 year cumulative recurrence rate was 8.2%. There was no
significant difference in 5 year local recurrence rate
between CT and CRT group (5.3% vs 14.3%, P = 0.140). Of
the 23 recured patients, 11 patients suffered from local
recurrence (7.8%), 17 patients had distant metastasis
(12.1%), both local and distant failures happened to 5 pa-
tients (3.5%). Liver was the most common site of metastasis
(39.1%), then was the lung (30.4%). Until the last follow up
time, up to 20 patients died of rectal cancer, 1 patient died
of other reasons. The median local recurrence and distant
failure time were 44 months (range, 3–104 months) and
40 months (range, 3-104 months); The median survival
time after local recurrence and distant metastasis were
17 months (0–49 months) and 21 months (0–49 months).
Survival
The overall 5-year OS and DFS rates were 82.4% and
71.9% for the whole group (Figure 1, Figure 2). For the
CT and CRT groups, the 5-year OS rates were 83.3%
versus 72.4% (P = 0.931), respectively (Figure 3), and the
5-year LRFS rates were 81.7% versus 74.5% (P = 0.157)(Figure 4). The 5-year DFS rate was significantly better in
patients with ≤15 than in those with >15 examined lymph
nodes (P = 0.001, Figure 5).
Univariate analysis and cox regression
In the univariate analysis, preoperative level of CEA, the
number of lymph nodes retrieved (<15 and ≥ 15), the dif-
ferentiation of the tumor and the perirectal fat infiltration
Figure 1 Overall survival of all patients.
Figure 3 Overall survival rates with or without radiotherapy.
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survival rate (Table 2). In the multivariate analysis, pre-
operative level of CEA, number of lymph nodes and the
perirectal fat infiltration were independent factors associ-
ated with significantly worse DFS (Table 3).
Effect of radiotherapy on recurrence
Patients with mid to lower rectal cancer had a higher
local recurrence rate than those with upper rectal can-
cer, while the difference was not significant (P = 0.115).
No matter of the height of rectal cancer, radiation did not
make significant improvement in local recurrence rate
(Table 4). Similarly, local recurrence rate was also higher
in patients with ≤15 (13.6%) than in those with >15 (2.7%)
examined lymph nodes (P = .015). According to different
number of lymph nodes,the recurrence rate differed not
significantly between the CT and CRT groups (Table 5).
Discussion
Many studies showed the post-operative radiation could
decrease the rate of local relapse and improve survival
rate for stage II and III rectal cancer. While, with the
introduction and application of TME in rectal cancer
which significantly reduced the recurrence rate of resect-
able rectal cancer, the routine postoperative radiation
may not be necessary, especially for subgroup patients of
pT3N0 rectal cancer, with an “intermediate” risk for re-
currence. Oppositely, the new role of preoperative RT
has been confirmed for stage II or III rectal cancers. TheFigure 2 Disease-free survival of all patients.MRC CR07/NCIC-CTGC016 conducted a multicenter
randomized trial comparing preoperative radiotherapy
with selective postoperative chemoradiotherapy. The
median follow-up time was 4 years and it came to a re-
sult that preoperative radiotherapy significantly im-
proved the 5-year DFS and reduced local recurrence rate
[12]. To evaluate the value of pre-operative radiation for
patients with resectable rectal cancer who undergone
TME, a prospective randomized trial contained of 1861
was conducted. By comparing the outcome between the
TME group and pre-operative 5*5 Gy short-term radi-
ation plus TME group, the study showed that pre-
operative radiotherapy could significantly reduce the
local recurrence rate. The rate was 5.6% in pre-operative
radiation group while the TME group was 10.9% (P <
0.001) [13]. In the study of Kapiteijn [14], the local re-
currence rate at two years was 2.4% in the pre-operative
radiation plus TME group and 8.2 percent in the TME
group (P < 0.001), confirming that for patients received
TME, short-term preoperative radiotherapy reduces the
risk of local recurrence. As a result, many researchers
suggest pre-operative radiation has more advantage over
post-operative radiation. Because of the low local recur-
rence rate after an optimal TME surgery, the risk of add-
itional radiation in patients with T3N0 rectal cancer may
outweigh the potential advantages. Nissan et al. [6] re-
ported patients with pT3N0 rectal cancer had a 4.1%
local recurrence rate and 71.4% overall survival with
TME alone,and the local and distant RFS and DSS were
similar with pT2N0 rectal cancer. According to the re-
port of Merchant NB [15], the overall local recurrence
was 9% and overall survival was 75% for patients with
T3N0 rectal cancer who underwent surgery without ad-
juvant treatment. Also, many researches showed add-
itional postoperative radiotherapy did not alter local
recurrence or survival after TME in patients with stage
IIA rectal cancer [8,9]. They proposed addition postop-
erative radiation may be overtreatment for patients with
stage II A rectal cancer if they had no other risk factors.
A study conducted by Gunderson showed that patients
with T3N0 rectal cancer had similar prognosis with T1/
2 N1 rectal cancer,and the 5-year OS and DFS were 84%
Figure 4 Local-recurrence free survival rates with or without radiotherapy (N=141). The difference of the overall survival between the two
groups was not significant (P=0.157). CT chemotherapy, CRT chemoradiotherapy.
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group, and adding radiotherapy did not improve the sur-
vival, suggesting that a trimodality treatment approach
was unnecessary [16]. Moreover, the morbidities and
poor functional outcomes induced by radiotherapy al-
ways affect the life quality of patients. Ooi reported that
for rectal patients receiving postoperative radiotherapy,
the acute toxicities incidence rate is ranging from 4%-
48% and 3%–10% of cases need hospitalization care [17].
In the long-term, radiation associated morbidities and
dysfunctional outcomes such as fibrosis, autonomic
nerve injury, bladder and sexual dysfunction were more
common in patients receiving pelvic radiation compared
to those without radiation [18-21]. Thus, for the patients
with pT3N0 rectal cancer, the role of radiotherapy needs
to be carefully evaluated.
In our retrospective analysis of 141 patients with
T3N0 rectal cancer,we found that the 5-year OS and
LRFS were not significantly different between CT and
CRT group (Figure 3, Figure 4). The 5-year OS, DFS andFigure 5 Disease-free survival rates with <15 and those ≥15 lymph nolocal recurrence rate of the whole group were 82.4%,
71.9% and 7.8%, respectively; similar with the previous
reports [7-9,16,22,23]. In terms of the effect of radiation
on local recurrence rate,we found that no matter the
number of lymph nodes,there was no significant differ-
ence between the CT and CRT groups. For the different
height of the rectal cancer, radiation did not affect the
recurrence rate of them either.
The risk factors that associated with the local recur-
rence have been inconsistently reported in many studies.
In the study made by Nissan et al. [6], univariate analysis
showed the presence of LVI, abnormal preoperative
CEA, and older age were associated with pelvic recur-
rence, while the multivariate analysis showed only
abnormal preoperative CEA was independent factors
for DFS (RR =3.1; 95% confidence interval [CI], 1.2-8.1;
P = 0.01) and DSS(RR =2.9, 95% CI: 1.1-7.6, P = 0.02).
The involvement of the circumferential resection margin
and age >60 years were also reported associated with ad-
verse oncologic outcomes [9]. Merchant et al.showed thedes retrieved (P=0.001).
Table 2 The log-rank univariate analysis of patients
Factors Number 3-year DFS (%) 5-year DFS (%) χ2 P value
Age (year) 2.104 0.14
<50 45 85.4 76.9
≥50 96 78.8 55.4
Sex 1.208 0.272
Male 97 80.3 68.5
Female 44 83.7 69.7 6.563 0.010
Pre-operative CEA (n g/m L)
<5 100 87.4 74.1
≥5 41 65.1 52.7
Distance to anal (cm) 3.299 0.19
0-5 61 80.3 68.0
6-10 56 79.9 61.8
10-15 24
Operation type 1.958 0.162
Dixon 97 85.8 74.1
Miles 44 71.5 58.1
Histologic type 3.053 0.081
Adenocarcinoma 134 83.1
Mucinous adenocarcinoma 7 44.8
Grade of differentiated 29.906 0.000
Well 24 80.8 68
Moderately 113 83.5 68
Poor 4 4.7
Maximum diameter (cm) 0.106 0.74
<5 75 80.5 59.5
≥5 66 81.9 70.6
Number of retrieved lymph nodes 11.616 0.000
<5 66 68.2 57.4
≥5 75 93
Lymph-vascular invasion 0.087 0.768
Yes 9 85.7 22.4
No 132 81.6 71.9
Radiation 2.787 0.095
Yes 42 87.9 74.5
No 97 91.2 90.7
Perirectal fat infiltration 3.953 0.009
Yes 55 76.2 40.5
No 86 86.5 71.9
DFS: disease free survival; LRR: local recurrence rate.
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local recurrence [14]. Willett et al. reported that the
depth of perirectal fat invasion by the tumor was an in-
dependent factor affecting local recurrence [23]. The
study of Tepper et al. showed the number of lymphnodes inspected and the lower rectal cancer were risk
factors for local recurrence [24,25]. Recently, a prospect-
ive study using data from the MRC CR07 and NCIC-
CTG CO16 randomized clinical trial showed that a
negative circumferential resection margin and a superior











≥ 5 ng/m L)
1.271 0.420 9.136 0.003 1.563,8.120
DFS Number of
lymph nodes
(<15, ≥ 15) −1.774 0.553 10.280 0.001 0.057,0.502
Perirectal fat
infiltration
(Yes/No) 0.860 0.431 3.981 0.046 1.015,5.501
DFS Number of
lymph nodes





1.617 0.700 5.338 0.021 1.278,19.865
(Yes/No)
Table 5 The effect of radiotherapy on recurrence in
different number of lymph nodes
Number Recurrence
rate (%)
P value CT CRT P value
<15 13.6 0.115 4/37 (10.8%) 5/29 (17.2%) 0.693
≥15 2.7 — 1/62 (1.6%) 1/13 (7.7%) 0.319
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rence rates, while a superior plane of surgery was an inde-
pendent factor affecting the local recurrence rates [26]. In
our study, we found that the pre-operative level of CEA
and the number of lymph nodes inspected and perirectal
fat infiltration were the independent factors affecting the
5-year DFS and local recurrence rate. The 5-year DFS was
better and the recurrence rate was lower in patients with
≥15 than those with < 15 lymph nodes. According to a
research by Swanson, the 5-year relative survival rate for
T3N0M0 colon cancer was 64% if 1 or 2 lymph nodes
were examined and rose to 86% if 25 lymph nodes were
examined, the prognosis of T3N0 colon cancer is
dependent on the number of lymph nodes examined [27].
Vather et al. also reported for Stage II and III colonic can-
cer, lower 5-year mortality was associated with increasing
rates of nodal examination [28]. In the previous studies,
upper rectal cancers have lower local recurrence rates
than mid to lower rectal cancer [29-31]. In our study, we
also found that upper rectal cancers have lower recurrence
rates than mid to lower rectal cancer, though the diffe-
rence was not significant (P = .115). This negative result
may due to the small number of patients in our study and
increasing the cohort may make it significantly different.Table 4 The effect of radiotherapy on recurrence in
different height of rectal cancer
Distance Recurrence
rate (%)
P value CT CRT P value
0-5 cm 9.8 0.115 2/34 (5.9%) 4/27 (14.8%) 0.392
6-10 cm 8.9 — 3/44 (6.8%) 2/12 (16.7%) 0.289
11-15 cm 0 — 0/21 (0%) 0/3 (0%) —This study has several limitations as follows. Firstly, the
5-year OS and LRFS of CRT group were lower than those
of CT group. This may partially caused by our selection
bias, the patients got adjuvant radiotherapy have more
adverse factors such as lower tumor location(P = .003) and
less number of lymph nodes inspected (P = .001). Se-
condly, our study is a retrospective and nonrandomized
analysis with a small sample size, this may not be convin-
cing enough to prove the negative role of additional radi-
ation after TME surgery for patients with no risk factors.
Similarly, the little number of sample limits us to demon-
strate the positive role for the pT3N0 patients with risk
factors. However,we came to a result that was similar to
the previous studies which sample sizes were larger than
us. Thirdly, all of patients in our study were with negative
circumferential resection margins which limit us to clarify
the prognostic of patients with positive CRM. Lastly, with
respect to location, the local recurrence rate was not of
significant difference. A study with large sample will be
needed to investigate all of these problems.
Conclusion
Despite of limitations, we showed the additional radio-
therapy did not significantly improve the overall survival
and local recurrence rate in patients with pT3N0 rectal
cancer. The recurrence rate is quite low for patients in CT
group. If an optimal TME surgery operated by experi-
enced surgeons guarantee a low local recurrence rate, the
risk of post-operative recurrence can be improved through
postoperative CT for rectal cancer patients with few risk
factors. For these subgroup patients, adjuvant pelvic
radiation after TME needs to be further evaluation. A
prospective study is needed to confirm this conclusion.
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